Sildenafil to improve respiratory rehabilitation outcomes in COPD: A controlled trial

Isabel Blanco, Salud Santos, Joaqím Gea, Rosa Güell, Ferran Torres, Elena Gimeno-Santos, Diego A. Rodriguez, Jordi Vilaró, Begona Gómez, Josep Roca, Joan Albert Barberà

Research output: Contribution to journalArticleResearchpeer-review

98 Citations (Scopus)

Abstract

Pulmonary hypertension is a serious complication of chronic obstructive pulmonary disease (COPD) that currently has no established pharmacological treatment. This study aimed to assess whether concomitant treatment with sildenafil would enhance the results of pulmonary rehabilitation in patients with COPD and increased pulmonary arterial pressure (PAP). In this double-blind, randomised controlled trial patients received 20 mg sildenafil or placebo three times daily and underwent pulmonary rehabilitation for 3 months. The primary end-point was the gain in the cycle endurance time at a constant work-rate. Secondary end-points included performance in the incremental exercise test, 6-min walk distance and quality of life. 63 patients with severe COPD and moderately increased PAP were randomised. Cycle endurance time increased by 149 s (95% CI 26-518 s) in the sildenafil group and by 169 s (95% CI 0-768 s) in the placebo group (median change difference -7 s, 95% CI -540-244 s; p=0.77). Gains in the incremental exercise test, 6-min walk distance and quality of life at the end of the study did not differ between groups. Measurements of arterial oxygenation and adverse events were similar in both groups. In patients with severe COPD and moderately increased PAP, concomitant treatment with sildenafil does not improve the results of pulmonary rehabilitation in exercise tolerance. Copyright ©ERS 2013.
Original languageEnglish
Pages (from-to)982-992
JournalEuropean Respiratory Journal
Volume42
Issue number4
DOIs
Publication statusPublished - 1 Oct 2013

Fingerprint Dive into the research topics of 'Sildenafil to improve respiratory rehabilitation outcomes in COPD: A controlled trial'. Together they form a unique fingerprint.

Cite this